| 1 |
NCT02942368 |
Active, not recruiting |
Adaptive tDCS for Treatment-Resistant MDD |
- Depressive Disorder, Treatment-Resistant
|
|
Interventional
|
Not Applicable |
- Washington University School of Medicine
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Improvement in depressive symptoms as measured by mean change in the Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to end of the study.
|
25 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02942368 |
6610 |
|
April 14, 2017 |
June 2019 |
June 2020 |
October 24, 2016 |
October 18, 2018 |
|
- Washington University in Saint Louis
Saint Louis, Missouri, United States
|
|
| 2 |
NCT03207282 |
Recruiting |
Treatment Resistant Depression in America Latina |
- Depressive Disorder, Treatment-Resistant
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of Participants With Treatment Resistant Depression (TRD)
- Healthcare Resource Utilization in TRD Participants
- Demographic Characteristics of TRD Participants
- (and 13 more...)
|
387 |
All |
18 Years and older (Adult, Older Adult) |
NCT03207282 |
CR108329
54135419RSD4001 |
TRAL |
September 27, 2017 |
March 31, 2019 |
August 31, 2019 |
July 2, 2017 |
October 22, 2018 |
|
- Fundación para el Estudio y Tratamiento de las Enfermedades Mentales
Ciudad Autonoma De Buenos Aires, Argentina - CESASIN
Ciudad De Mendoza, Argentina - Instituto DAMIC
Cordoba, Argentina - (and 32 more...)
|
|
| 3 |
NCT03626181 |
Recruiting |
Biomarkers of Theta Burst Stimulation in Major Depressive Disorder |
- Depressive Disorder, Treatment-Resistant
|
- Device: Theta Burst Stimulation ( Transcranial Magnetic Stimulation)
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale
- 1. Montgomery-Åsberg Depression Rating Scale (MADRS)
- 2. Hamilton Anxiety rating Scale (HAM-A)
- (and 8 more...)
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03626181 |
10001858
RT # 10016954 |
|
July 6, 2018 |
July 1, 2019 |
July 1, 2019 |
August 10, 2018 |
August 10, 2018 |
|
- University of Calgary
Calgary, Alberta, Canada
|
|
| 4 |
NCT02153502 |
Completed |
Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment |
- Depressive Disorder, Treatment-Resistant
|
- Drug: AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Montgomery-Ǻsberg Depression Rating Scale (MADRS) total score
- 17-item Hamilton Rating Scale for Depression (HAM-D17)
- Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH ATRQ)
- (and 7 more...)
|
206 |
All |
18 Years and older (Adult, Older Adult) |
NCT02153502 |
14-AVP-786-201 |
|
July 2014 |
February 2016 |
February 2016 |
June 3, 2014 |
May 15, 2017 |
|
- Birmingham, Alabama, United States
- Birmingham, Alabama, United States
- Bellflower, California, United States
- (and 29 more...)
|
|
| 5 |
NCT00768430 |
Completed
Has Results |
Optimization of IV Ketamine for Treatment Resistant Depression |
- Major Depressive Disorder (MDD)
- Treatment Resistant Depression (TRD)
|
- Drug: Ketamine
- Drug: Midazolam
|
Interventional
|
Phase 2 |
- Baylor College of Medicine
- Icahn School of Medicine at Mount Sinai
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
|
73 |
All |
21 Years to 80 Years (Adult, Older Adult) |
NCT00768430 |
GCO 07-0114 |
|
November 2008 |
September 2012 |
November 2012 |
October 8, 2008 |
January 31, 2014 |
January 31, 2014 |
- Mount Sinai School of Medicine
New York, New York, United States - Michael E. Dabakey VA Medical Center & Baylor College of Medicine
Houston, Texas, United States
|
|
| 6 |
NCT01435148 |
Unknown † |
Deep Brain Stimulation in Treatment Resistant Depression |
- Treatment Resistant Depression
|
- Procedure: Deep Brain Stimulation, implanted
|
Interventional
|
Not Applicable |
- North Bristol NHS Trust
- University of Bristol
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
|
- Decrease in Montgomery and Asberg Rating Scale score of at least 50% at an average of 18 months after implantation.
- Clinical Global Impression Improvement Scale(CGI-I). Score <4.
- Global Assessment of Functioning scale, an improvement of >1/2(100-initial score)
- A decrease of 50% in Hamilton Depression Rating Scale (17 items) at End of contact selection and adjustment plus 6 months. An average of 18 months after implantation
|
8 |
All |
18 Years and older (Adult, Older Adult) |
NCT01435148 |
1759
06/Q2001/189 |
|
December 2006 |
December 2012 |
December 2012 |
September 15, 2011 |
September 15, 2011 |
|
- Neurosurgey Department, Frenchay Hospital
Bristol, United Kingdom
|
|
| 7 |
NCT03051256 |
Recruiting |
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg Daily and 50 mg Daily of REL-1017 in Major Depressive Disorder |
- Depressive Disorder, Major
- Depressive Disorder, Treatment-Resistant
|
- Drug: REL-1017
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Relmada Therapeutics, Inc.
- INC Research
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Incidence of treatment emergent adverse events (AEs) [Safety and Tolerability]
- ECG parameters [Safety]
- Clinical laboratory tests [Safety]
- (and 9 more...)
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03051256 |
REL-1017-202 |
|
May 11, 2018 |
May 2019 |
May 2019 |
February 13, 2017 |
July 25, 2018 |
|
- Woodland International Research Group
Little Rock, Arkansas, United States - Collaborative Neuroscience Network, LLC
Garden Grove, California, United States - Artemis Institute for Clinical Research
San Diego, California, United States - (and 6 more...)
|
|
| 8 |
NCT03653858 |
Recruiting |
Efficacy Study of Deep Brain Stimulation in Patients With Treatment Resistant Major Depression |
- Treatment-resistant Depression
|
- Device: Vercise GEVIA deep brain stimulation (DBS) system
|
Interventional
|
Not Applicable |
- University Hospital Freiburg
- Boston Scientific Corporation
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Montgomery-Asberg Depression Rating Scale (MADRS) total score
- Time to Montgomery-Asberg Depression Rating Scale (MADRS) augmentation of >5 points or clinical worsening in two consecutive visits after DBS termination
- Assessment of (Serious) Adverse Events related to Investigational Medical Device and / or surgical procedures
- (and 31 more...)
|
47 |
All |
20 Years to 75 Years (Adult, Older Adult) |
NCT03653858 |
P000767
DRKS00014947
CIV-17-07-020746 |
FORESEE III |
September 3, 2018 |
June 2, 2022 |
June 2, 2023 |
August 31, 2018 |
September 20, 2018 |
|
- University Hospital Freiburg
Freiburg, Baden-Württemberg, Germany - University Hospital Bonn
Bonn, Nordrhein-Westfalen, Germany
|
|
| 9 |
NCT03537794 |
Not yet recruiting |
Characterizing Dopamine Receptor Binding in Treatment Resistant Depression |
- Treatment Resistant Depression
|
- Diagnostic Test: PET scans
|
Observational
|
|
- St. Michael's Hospital, Toronto
- Centre for Addiction and Mental Health
|
Other |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
|
45 |
All |
25 Years to 55 Years (Adult) |
NCT03537794 |
TPET-01 |
|
June 2018 |
June 2021 |
June 2021 |
May 25, 2018 |
May 25, 2018 |
|
|
|
| 10 |
NCT01945047 |
Completed |
Action of Ketamine in Treatment-Resistant Depression |
- Treatment-resistant Depression
|
- Drug: Ketamine
- Drug: Midazolam
|
Interventional
|
Phase 2
Phase 3 |
- University of Ottawa
- Canadian Institutes of Health Research (CIHR)
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Efficacy of Ketamine over Midazolam in double blind study for efficacy of relief for Major Depressive Disorder
- Ketamine for use in relief of Major Depressive Disorder over repeated administration
- To determine the role of genetic polymorphisms in the participants response to ketamine infusion
|
46 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01945047 |
REB2012023 |
|
May 2013 |
December 2017 |
December 2017 |
September 18, 2013 |
June 25, 2018 |
|
- Institute of Mental Health Research, Royal Ottawa Hospital
Ottawa, Ontario, Canada
|
|
| 11 |
NCT01944644 |
Completed
Has Results |
Low Field Magnetic Stimulation for Treatment Resistant Depression |
- Treatment Resistant Depression
|
- Device: Active Low Field Magnetic Stimulation
- Device: Sham Low Field Magnetic Stimulation
|
Interventional
|
Not Applicable |
- Weill Medical College of Cornell University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- 6 Item Hamilton Depression Rating Scale
- Visual Analog Scale
- Positive and Negative Affect Score (PANAS) - Negative Subscale
- Positive and Negative Affect Score (PANAS) - Positive Subscale
|
66 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01944644 |
1207012777 |
|
August 2013 |
May 2016 |
May 2016 |
September 17, 2013 |
September 17, 2018 |
September 17, 2018 |
- Weill Cornell Medical College
New York, New York, United States
|
|
| 12 |
NCT03257397 |
Recruiting |
TBS in Major Depression |
- Treatment Resistant Depression
|
- Device: theta-burst stimulation (TBS) using a MagPro X1000
|
Interventional
|
Phase 4 |
- Rupert Lanzenberger
- Medical University of Vienna
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- HAMD
- BDI-II
- Regional white matter microstructure using DWI
- Regional grey matter volume and using MRI
|
80 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03257397 |
PSY-NIL-0008 |
|
August 1, 2017 |
July 31, 2020 |
December 31, 2020 |
August 22, 2017 |
August 22, 2017 |
|
- Department of Psychiatry and Psychotherapy, Medical University of Vienna
Vienna, Austria
|
|
| 13 |
NCT01031810 |
Terminated
Has Results |
PET Biomarkers in Treatment Resistant Depression |
- Major Depressive Disorder
|
|
Interventional
|
Phase 4 |
- New York State Psychiatric Institute
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale Scores 17 at Baseline
- Hamilton Depression Rating Scale Scores 17 at week12
- Quick Inventory of Depression- Self Report 16
|
13 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01031810 |
6025
RC1MH088405-01 |
|
November 2009 |
March 2013 |
March 2013 |
December 15, 2009 |
September 18, 2014 |
September 18, 2014 |
- New York State Psychiatric Institute
New York, New York, United States
|
|
| 14 |
NCT02456948 |
Recruiting |
Adjunct Minocyline in Treatment-resistant Depression |
- Major Depressive Disorder
|
- Drug: Minocycline
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Charite University, Berlin, Germany
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Response as per MADRS (Montgomery-Åsberg Depression Rating Scale)
- Remission as per MADRS (Montgomery-Åsberg Depression Rating Scale)
- HAM-D-17-Scale (17-item Hamilton Depression Rating Scale)
- (and 5 more...)
|
160 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02456948 |
01EE1401F |
Mino-TRD |
December 2015 |
February 2019 |
February 2019 |
May 29, 2015 |
July 21, 2017 |
|
- Heidelberg University Hospital, Department of Psychiatry
Heidelberg, Baden-Württemberg, Germany - Department of Psychiatry, Universitiy Hospital
Erlangen, Bavaria, Germany - Department of Psychiatry, LMU Munich
Munich, Bavaria, Germany - (and 4 more...)
|
|
| 15 |
NCT01515215 |
Completed |
Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depressive Disorder |
- Major Depressive Disorder
|
- Device: Repetitive Transcranial Magnetic Stimulation
|
Interventional
|
Not Applicable |
- Centre for Addiction and Mental Health
- Ontario Mental Health Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Degree of Change in HAM-D17 Scores
- Degree of Change in Montgomery-Asberg Depression Rating Scale Scores
- Degree of Change in Beck Depression Inventory Scores
- (and 2 more...)
|
107 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT01515215 |
040 / 2008 |
|
July 2008 |
October 2016 |
October 2016 |
January 24, 2012 |
November 1, 2016 |
|
- Centre for Addiction and Mental Health
Toronto, Ontario, Canada
|
|
| 16 |
NCT01598324 |
Terminated |
Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder |
- Treatment-Resistant Depression
|
|
Observational
|
|
- Mclean Hospital
- Pfizer
- Massachusetts General Hospital
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Glutamate level in antidepressant non-responders
- Glutamine level in treatment-responders following six weeks of antidepressant and non-responders following six weeks of adjunctive treatment.
- Glutamine level in treatment-responders following six weeks of antidepressant and non-responders following six weeks of adjunctive treatment
- (and 5 more...)
|
1 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01598324 |
WS2058787 |
|
July 2012 |
April 2013 |
|
May 15, 2012 |
August 13, 2013 |
|
- McLean Hospital - McLean Imaging Center
Belmont, Massachusetts, United States
|
|
| 17 |
NCT00646087 |
Withdrawn |
Ketamine Frequency Treatment for Major Depressive Disorder |
- Treatment Resistant Depression
|
- Drug: Ketamine
- Drug: Ketamine/Saline
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The primary efficacy measure is the change in scores in the 21-item Hamilton Depression Rating Scale.
- Proportion of patients with remission (HDRS score < 18) at the end of the 2-week treatment and each follow-up contact.
|
0 |
All |
30 Years to 65 Years (Adult, Older Adult) |
NCT00646087 |
04-07-04 |
|
March 2008 |
|
|
March 28, 2008 |
June 6, 2011 |
|
- St. Mary's Duluth Clinic Health System
Duluth, Minnesota, United States
|
|
| 18 |
NCT03573349 |
Not yet recruiting |
Glutamate MRS During Ketamine Infusion |
- Major Depressive Disorder
- Treatment Resistant Depression
|
|
Interventional
|
Early Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in glutamate and correlation with change in depression symptoms measured with MADRAS
|
10 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03573349 |
17-011373 |
|
November 2018 |
August 2019 |
December 2019 |
June 29, 2018 |
November 7, 2018 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
|
| 19 |
NCT00704860 |
Completed |
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism |
|
- Other: Open label pharmacotherapy
|
Interventional
|
Phase 4 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Sustained Remission from Depression and Hippocampal Atrophy
- 5-HT1a Genetic Markers
|
27 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00704860 |
REB- 200506 |
|
February 2005 |
November 2009 |
December 2010 |
June 25, 2008 |
January 19, 2011 |
|
- University of Ottawa Institute of Mental Health Research
Ottawa, Ontario, Canada
|
|
| 20 |
NCT02452892 |
Completed
Has Results |
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD) |
- Depression
- Depressive Disorder
- Depressive Disorder, Treatment-resistant
- Depressive Disorder, Major
|
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline to ( Day 4) in the 6-item Hamilton Rating Scale for Depression (HAM-D6) Total Score.
- Change From Day 4 in HAM-D6 Total Score at Day 11 for Week 1 Non-responders: Response to 120 Minutes LFMS
- Day 4 Responders: Persistence of Effect Based on Pre-specified HAM-D6 Total Score
|
122 |
All |
18 Years and older (Adult, Older Adult) |
NCT02452892 |
TAL-02-007 |
|
September 2015 |
September 2016 |
October 2016 |
May 25, 2015 |
December 5, 2017 |
December 5, 2017 |
- CNS Trials
Garden Grove, California, United States - Synergy Escondido
Lemon Grove, California, United States - Pacific Trials Partners
Oakland, California, United States - (and 9 more...)
|
|
| 21 |
NCT00320372 |
Completed
Has Results |
Treatment-Resistant Depression Registry |
- Major Depressive Disorder
|
|
Observational
|
|
|
Industry |
- Time Perspective: Prospective
|
- Montgomery Asberg Depression Rating Scale (MADRS)% Responders (>/= 50% Improvement From Baseline)
- Time Until Recurrence (TUR) for Patients That Achieved Remission, Based on Montgomery Asberg Depression Rating Scale (MADRS)
- Montgomery Asberg Depression Rating Scale (MADRS)% Remitters (MADRS Total Score ≤9 at Visit Month Assessment Post-Baseline)
- (and 4 more...)
|
795 |
All |
18 Years and older (Adult, Older Adult) |
NCT00320372 |
TRD Registry |
|
January 2006 |
March 2015 |
May 2015 |
May 3, 2006 |
December 23, 2015 |
December 23, 2015 |
- University of Arizona
Tucson, Arizona, United States - Cedars-Sinai Hospital
Beverly Hills, California, United States - Mark Zetin, MD - Private Practice
Garden Grove, California, United States - (and 52 more...)
|
|
| 22 |
NCT02900092 |
Completed |
Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone |
- Major Depressive Disorder
|
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Montgomery-Asberg Depression (MADRS) Scale
|
10 |
Female |
50 Years to 75 Years (Adult, Older Adult) |
NCT02900092 |
2016P001182 |
|
November 2016 |
January 12, 2018 |
January 12, 2018 |
September 14, 2016 |
September 14, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 23 |
NCT00871299 |
Completed |
Practicing Alternative Techniques to Heal From Depression: The PATH-D Study |
- Major Depressive Disorder
|
- Behavioral: Mindfulness Based Cognitive Therapy
- Behavioral: Health Enhancement Program and medication management
|
Interventional
|
Not Applicable |
- University of California, San Francisco
- National Center for Complementary and Integrative Health (NCCIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale (HAMD-17)
- Quick Inventory of Depressive Symptomatology(Self-Rated)-16 items(QIDS-SR16)
- Short Form Health Survey-36
- (and 3 more...)
|
173 |
All |
18 Years and older (Adult, Older Adult) |
NCT00871299 |
R01 AT004572-O1A1
R01AT004572-01A1
3063975 |
PATH-D |
September 2009 |
June 2014 |
June 2014 |
March 30, 2009 |
December 2, 2014 |
|
- University of California, San Francisco
San Francisco, California, United States
|
|
| 24 |
NCT01935115 |
Completed |
Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy |
- Treatment Resistant Depression
|
- Drug: Propofol
- Drug: Ketamine
|
Interventional
|
Phase 4 |
- University of Saskatchewan
- Saskatoon Health Region
- Royal University Hospital Foundation
- Schulman Research Award
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The primary outcome is defined as the number of ECT treatments required to reach a 50% reduction in baseline MADRS (Montgomery-Asberg Depression Scale) score.
- Change in CADSS (Clinician Administered Dissociative States Scale)
- Change in ALS-18 (Affective Lability Scale)
- (and 7 more...)
|
27 |
All |
18 Years and older (Adult, Older Adult) |
NCT01935115 |
UofSKetamine-01 |
|
September 2013 |
March 2016 |
March 2016 |
September 4, 2013 |
September 13, 2017 |
|
- Royal University Hospital
Saskatoon, Saskatchewan, Canada
|
|
| 25 |
NCT00789854 |
Completed
Has Results |
Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients |
- Major Depressive Disorder
- Treatment Resistant Depression
|
- Drug: Quetiapine XR
- Drug: Lithium carbonate
- Drug: SSRI/Venlafaxine
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Per Protocol Analysis Set)
- Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Modified Intention to Treat Analysis Set)
- Depression Remission; Montgomery-Asberg Depression Rating Scale MADRS ≤10, All Patients
- (and 27 more...)
|
688 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00789854 |
D1443L00044 |
RUBY |
November 2008 |
August 2009 |
August 2009 |
November 13, 2008 |
May 23, 2012 |
May 23, 2012 |
- Research Site
Garran, Australian Capital Territory, Australia - Research Site
Brisbane, Queensland, Australia - Research Site
Everton Park, Queensland, Australia - (and 103 more...)
|
|
| 26 |
NCT02141776 |
Completed |
Comparison of Anodal Transcranial Direct Current Stimulation (t-DCS) and Sham Stimulation in Patients With Treatment-resistant Depression |
- Major Depressive Disorder
|
- Device: Transcranial direct current stimulation (t-DCS)
- Other: Sham Controlled Arm
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Montgomery Asberg depression rating scale score
|
3 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT02141776 |
95-2013
IRB201501014 |
|
May 2014 |
January 8, 2018 |
January 8, 2018 |
May 19, 2014 |
January 12, 2018 |
|
- Univ of Florida
Gainesville, Florida, United States
|
|
| 27 |
NCT02922725 |
Recruiting |
Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females |
- Major Depressive Disorder
|
- Drug: 5-hydroxytryptophan and Creatine
- Other: Placebo control
|
Interventional
|
Phase 4 |
- Brent Kious
- University of Utah
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change from Baseline in Hamilton Depression Rating Scale
|
54 |
Female |
25 Years to 40 Years (Adult) |
NCT02922725 |
94176 |
|
November 2016 |
October 2018 |
October 2019 |
October 4, 2016 |
December 7, 2017 |
|
- University of Utah
Salt Lake City, Utah, United States
|
|
| 28 |
NCT01983904 |
Active, not recruiting |
DBS for Treatment Resistant Depression |
- Depressive Disorder, Treatment-Resistant
|
- Device: deep brain stimulation with short & long pulse width
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Hamilton Depression Rating Scale
- Change from baseline on Illness Density Index, Montgomery-Asberg Depression Rating Scale and Hamilton Anxiety Scale, Positive and Negative Affect Scale, Clinical Global Impression of Change, GAF< SAs, NAS, Q-LES-Q-SF & neuropsychological tests
- Post Cognitive Behavioural Therapy Scores
|
25 |
All |
20 Years to 70 Years (Adult, Older Adult) |
NCT01983904 |
E-20948 |
CRIO-DBS |
August 2013 |
December 2017 |
March 2018 |
November 14, 2013 |
October 26, 2017 |
|
- University of Calgary & Alberta Health Services, Foothills Medical Centre
Calgary, Alberta, Canada
|
|
| 29 |
NCT00035321 |
Completed |
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression |
- Major Depressive Disorder
|
- Drug: Olanzapine
- Drug: Fluoxetine
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- To assess the efficacy of up to 8 weeks of treatment with OFC versus olanzapine and fluoxetine monotherapies, in patients with recurrent MDD without psychotic features
- who meet study criteria for TRD, as measured by last observation carried forward (LOCF) mean change from baseline to endpoint in the MADRS total score
- Treatment-resistant depression will be defined as:historic failure to achieve satisfactory response to an antidepressant (other than fluoxetine) during the current MDD episode
- (and 18 more...)
|
600 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00035321 |
6272
H6P-MC-HDAO |
|
April 2002 |
|
July 2005 |
May 3, 2002 |
July 24, 2006 |
|
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Oceanside, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
San Marcos, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Torrance, California, United States - (and 30 more...)
|
|
| 30 |
NCT01640080 |
Completed |
A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression |
- Major Depressive Disorder
|
- Drug: Esketamine
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change from Day 1 (baseline) to Day 2 in the Montgomery Asberg Depression Rating Scale (MADRS) total score in the double-blind treatment phase
- Change from Day 1 (baseline) to Day 4 in Major Depressive Disorder (MDD) symptoms using the Montgomery Asberg Depression Rating Scale (MADRS) total score in the double-blind treatment phase
- Change from Day 1 (baseline) to Day 35 in Major Depressive Disorder (MDD) symptoms using the Montgomery Asberg Depression Rating Scale (MADRS) total score during the posttreatment phase
- (and 11 more...)
|
30 |
All |
18 Years to 64 Years (Adult) |
NCT01640080 |
CR100843
ESKETIVTRD2001
2011-005992-17 |
|
June 2012 |
June 2013 |
June 2013 |
July 13, 2012 |
April 22, 2016 |
|
- Dave, Belgium
- Gent, Belgium
- Kortenberg, Belgium
- (and 6 more...)
|
|
| 31 |
NCT02752178 |
Completed |
Peripheral Immunomarker Validation in Treatment-resistant Depression |
- Depressive Disorder, Major
|
|
Observational
|
|
- University of Cambridge
- University of Oxford
- University of Glasgow
- (and 5 more...)
|
Other / Industry |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- C-reactive protein (CRP) levels (mg/l)
- Flow cytometric immunophenotype
- Structural parameters of the brain
- (and 3 more...)
|
393 |
All |
25 Years to 50 Years (Adult) |
NCT02752178 |
15/EE/0092 |
BIODEP |
June 2015 |
September 2018 |
September 2018 |
April 26, 2016 |
September 25, 2018 |
|
- University of Sussex
Brighton, United Kingdom - University of Cambridge
Cambridge, United Kingdom - University of Glasgow
Glasgow, United Kingdom - (and 2 more...)
|
|
| 32 |
NCT01627782 |
Completed
Has Results |
A Study of Ketamine in Patients With Treatment-resistant Depression |
- Major Depressive Disorder
|
- Drug: Placebo
- Drug: Ketamine
|
Interventional
|
Phase 2 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 15
- Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 29
- Number of Responders Based on Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
- (and 13 more...)
|
68 |
All |
18 Years to 64 Years (Adult) |
NCT01627782 |
CR100886
KETIVTRD2002 |
|
August 2012 |
September 2013 |
September 2013 |
June 26, 2012 |
August 5, 2016 |
August 5, 2016 |
- Birmingham, Alabama, United States
- Little Rock, Arkansas, United States
- Centennial, Colorado, United States
- (and 10 more...)
|
|
| 33 |
NCT00667680 |
Completed |
Transcranial Direct Current Stimulation (tDCS) in Treatment-resistant Depression |
- Therapy Resistant Major Depression
|
- Device: Transcranial direct current stimulation (tDCS) - Eldith DC-Stimulator
|
Interventional
|
Phase 2 |
- Ludwig-Maximilians - University of Munich
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Psychiatric Rating Scale for Depression (HRSD-24)
- Beck depression Inventory (BDI) Clinical Global Impression (CGI) Mini-Mental-Status-Test (MMST) Verbal Learning and Memory Test (VLMT) Regensburger Word Fluency Test (RWT)
|
20 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT00667680 |
01/2007 |
|
March 2007 |
September 2008 |
November 2008 |
April 28, 2008 |
November 16, 2009 |
|
- Department of Psychiatry and Psychotherapy, Ludwig-Maximilian University Munich
Munich, Germany
|
|
| 34 |
NCT00531726 |
Completed |
Berlin Deep Brain Stimulation Depression Study |
- Treatment Resistant Depression
|
|
Interventional
|
Not Applicable |
- Charite University, Berlin, Germany
- University Hospital Carl Gustav Carus
- Ludwig-Maximilians - University of Munich
- Hannover Medical School
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- HAMD/MARS score reduction
- neurotrophic factor concentration, p300, cortical excitability measures, stress axis measures
|
11 |
All |
25 Years to 80 Years (Adult, Older Adult) |
NCT00531726 |
BDDS |
BDDS |
September 2007 |
September 2012 |
September 2013 |
September 19, 2007 |
January 24, 2018 |
|
- Charité - Universitaetsmedizin Berlin
Berlin, Germany
|
|
| 35 |
NCT00367003 |
Recruiting |
Deep Brain Stimulation for Treatment Resistant Depression |
- Major Depressive Disorder
|
- Device: Deep Brain Stimulator, implantable
|
Interventional
|
Not Applicable |
- Emory University
- The Dana Foundation
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- decrease in Hamilton Depression Rating Scale-24 score of at least 50% at 6 months open treatment
|
20 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00367003 |
IRB00024883 |
|
September 2006 |
November 2019 |
November 2019 |
August 22, 2006 |
November 7, 2018 |
|
- Emory University School of Medicine
Atlanta, Georgia, United States
|
|
| 36 |
NCT03642522 |
Not yet recruiting |
Investigating Predictors of Treatment Response in Treatment-Resistant Depression (TRD) With Interleaved TMS/fMRI |
- Major Depressive Disorder
- Depression
|
- Device: repetitive transcranial magnetic stimulation
|
Interventional
|
Not Applicable |
- University of British Columbia
- University of Victoria
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Inventory of Depressive Symptomatology (IDS-30)
- Quick Inventory of Depressive Symptomatology (QIDS-SR)
|
50 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03642522 |
H14-02819 |
|
September 1, 2018 |
December 31, 2019 |
December 31, 2020 |
August 22, 2018 |
August 22, 2018 |
|
- Non-Invasive Neurostimulation Therapies lab, University of British Columbia
Vancouver, British Columbia, Canada
|
|
| 37 |
NCT01438242 |
Withdrawn |
An Open Label Study of the Genecept™ Assay in Treatment Resistant Depression |
- Major Depressive Disorder
|
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Efficacy
- Medication Adherence
- Resource Utilization
- (and 2 more...)
|
0 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01438242 |
AT1 |
|
January 2015 |
January 2016 |
January 2016 |
September 22, 2011 |
March 23, 2015 |
|
- Genomind, LLC
Chalfont, Pennsylvania, United States
|
|
| 38 |
NCT00953745 |
Completed
Has Results |
Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression |
- Major Depressive Disorder
|
- Drug: Escitalopram
- Drug: Aripiprazole
- Drug: Placebo Capsule
- Drug: Placebo Tablet
|
Interventional
|
Not Applicable |
- Washington University School of Medicine
- Bristol-Myers Squibb
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Other
|
- Fluorodopa Uptake Values in Brain Images of Aripiprazole Augmentation Responders
- Depression Symptom Change on The Montgomery-Åsberg Depression Rating (MADRS) Scale Between ARP Responders and Non-responders.
|
43 |
All |
18 Years to 55 Years (Adult) |
NCT00953745 |
201101790-2 |
|
May 2009 |
June 2012 |
December 2012 |
August 6, 2009 |
April 19, 2018 |
April 19, 2018 |
- Washington University in St. Louis, School of Medicine
Saint Louis, Missouri, United States
|
|
| 39 |
NCT01431001 |
Completed |
Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression |
- Major Depressive Disorder
|
- Device: Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Remission from depression
- Safety and tolerability of rTMS
|
40 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01431001 |
NS-CPS-TRMD-1 |
|
October 2011 |
October 2013 |
October 2013 |
September 9, 2011 |
May 19, 2014 |
|
- Emory University
Atlanta, Georgia, United States - Rush Medical College
Chicago, Illinois, United States - Medical University of South Carolina
Charleston, South Carolina, United States - Monash Alfred Psychiatry Research Centre
Melbourne, Victoria, Australia
|
|
| 40 |
NCT01798407 |
Recruiting |
DBS of the Lateral Habenula in Treatment-Resistant Depression |
- Treatment Resistant Major Depressive Disorder
|
- Device: Activa Tremor Control Sys (DBS Implant)
- Other: Randomized, staggered withdrawal phase
|
Interventional
|
Not Applicable |
- Wayne Goodman MD
- Baylor College of Medicine
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in HDRS^17 score from baseline to 6 months after the commencement of stimulation
- MADRS (Montgomery and Asberg Depression Rating Scale)
- Clinical Global Impression of Severity (CGI-S)
- (and 8 more...)
|
6 |
All |
21 Years to 70 Years (Adult, Older Adult) |
NCT01798407 |
H40307
49593
277909
HSM#12-00467
GCO 12-1815 |
|
February 2013 |
August 2019 |
February 2020 |
February 25, 2013 |
September 13, 2018 |
|
- Baylor College of Medicine
Houston, Texas, United States
|
|
| 41 |
NCT01677078 |
Completed |
Coupling Repetitive Transcranial Magnetic Stimulation With a Neuronavigation System in Treatment Resistant Depression |
- Treatment Resistant Depression
|
- Device: Neuronavigation system
- Device: Standard localisation method
|
Interventional
|
Not Applicable |
- Rennes University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Response
- Remission
- MADRS
- (and 2 more...)
|
107 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01677078 |
2011-A01272-39 |
TMS |
January 21, 2013 |
March 25, 2017 |
March 25, 2017 |
August 31, 2012 |
August 31, 2018 |
|
- Centre Santé Mentale Angevin CESAME
Angers, France - CHU de Brest
Brest, France - Etablissement Public de Santé Mentale
Quimperlé, France - (and 2 more...)
|
|
| 42 |
NCT01555021 |
Terminated
Has Results |
Pharmacogenomics for Antidepressant Guidance and Education |
- Treatment Resistant Depression
|
- Genetic: Genotyping assays
|
Observational
|
|
- Massachusetts General Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in Quick Inventory of Depressive Symptoms-Self Rating (SR) 16 Item
- Clinician's Report That AGT Modified His/Her Decision Regarding Which Antidepressant to Prescribe.
- Treatment Adherence
- Adverse Events (Side Effects)
|
4 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01555021 |
2011-P-001921 |
|
December 2011 |
July 2012 |
July 2012 |
March 15, 2012 |
November 5, 2018 |
November 5, 2018 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 43 |
NCT01128452 |
Terminated |
Safety and Efficacy of EVT 101 in Treatment-Resistant Depression |
|
- Drug: EVT 101
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Janssen Research & Development, LLC
- Hoffmann-La Roche
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Safety and Tolerability Profile of EVT 101
- Efficacy of EVT 101 in depression measured using the MADRS score
- Percentage of patients who respond to treatment with study drug
- Percentage of patients who experience remission
|
8 |
All |
18 Years to 55 Years (Adult) |
NCT01128452 |
CR104589
RRA-12001, EVT 101/1012 |
|
June 2010 |
March 2011 |
March 2011 |
May 21, 2010 |
March 28, 2016 |
|
- Evotec Study Site 6
Oceanside, California, United States - Evotec Study Site 19
San Diego, California, United States - Evotec Study Site 15
Tampa, Florida, United States - (and 11 more...)
|
|
| 44 |
NCT00296686 |
Terminated |
Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression |
|
- Drug: Tranylcypromine
- Drug: Dextroamphetamine
- Drug: Triiodothyronine
|
Interventional
|
Phase 4 |
- New York State Psychiatric Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hamilton Depression Scale (HAM-D)
- Beck Depression Inventory (BDI)
- Clinical Global Impression (CGI)
- Patient Global Impression (PGI)
|
31 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00296686 |
#4213 |
|
September 2001 |
August 2006 |
August 2006 |
February 27, 2006 |
April 27, 2012 |
|
- Depression Evaluation Service - New York State Psychiatric Institute
New York, New York, United States
|
|
| 45 |
NCT02046330 |
Recruiting |
Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression |
- Major Depressive Disorder
- Treatment Resistant Depression
|
- Device: Deep Brain Stimulation Model 3387 Model 3389
|
Interventional
|
Not Applicable |
- The University of Texas Health Science Center, Houston
- Medtronic
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Changes in patients MADRS scores
- Accuracy of Electrode placement
- Frequency and Charge of Stimulation
- (and 4 more...)
|
10 |
All |
22 Years to 65 Years (Adult, Older Adult) |
NCT02046330 |
HSC-MS-13-0004 |
|
November 2013 |
November 2022 |
November 2022 |
January 27, 2014 |
March 30, 2018 |
|
- UT Center of Excellence on Mood Disorders
Houston, Texas, United States
|
|
| 46 |
NCT03435744 |
Not yet recruiting |
Simvastatin as an Augmentation Treatment for Treatment Resistant Depression: Randomized Controlled Trial. |
- Treatment Resistant Depression
- Major Depressive Disorder
|
- Drug: Simvastatin 20 mg
- Other: Placebo Oral Tablet
|
Interventional
|
Phase 3 |
- Pakistan Institute of Living and Learning
- King's College London
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Montgomery-Asberg Depression Rating Scale (MADRS; Montgomery Asberg, 1979)
|
150 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03435744 |
PILL-DepSTAT-001 |
DepSTAT |
April 1, 2018 |
March 30, 2020 |
December 31, 2020 |
February 16, 2018 |
February 16, 2018 |
|
|
|
| 47 |
NCT01973478 |
Active, not recruiting |
Deep Brain Stimulation in Patients With Chronic Treatment Resistant Depression |
- Major Depressive Disorder
- Recurrent Depressive Disorder
- Bipolar Disorder
|
|
Interventional
|
Phase 3 |
- Rennes University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Response = 50 % decrease of the HDRS-17 (Hamilton depression rating scale, 17 items version) (yes/no)
- Remission (yes/no)
- CGI (Clinical global impressions) amelioration (yes/no)
- (and 9 more...)
|
40 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01973478 |
35RC08_8902 |
STHYM |
May 2014 |
March 2018 |
February 2020 |
October 31, 2013 |
August 22, 2017 |
|
- CHU
Bordeaux, France - CHU
Clermont Ferrand, France - CHU
Grenoble, France - (and 12 more...)
|
|
| 48 |
NCT01234558 |
Completed |
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression |
- Major Depressive Disorder
|
|
Interventional
|
Phase 2 |
- Naurex, Inc, an affiliate of Allergan plc
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in depression score
- Change in BPRS+
|
115 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01234558 |
GLYX13-C201 |
|
May 2011 |
June 2012 |
July 2012 |
November 4, 2010 |
September 12, 2012 |
|
- Mulitple
Evanston, Illinois, United States
|
|
| 49 |
NCT01921543 |
Terminated |
Deep Brain Stimulation in Treatment Refractory Depression |
- Major Depressive Disorder
|
- Device: ITP Stimulation
- Device: CI/BNST stimulation
- Device: No stimulation
|
Interventional
|
Phase 1
Phase 2 |
- Universitaire Ziekenhuizen Leuven
- Medtronic
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in depressive symptoms as measured by the 17-item Hamilton Depression Rating Scale
- Montgomery- Asberg Depression Rating Scale (MADRS)
- Inventory for Depressive Symptoms, Self-Report (IDS-SR)
- (and 8 more...)
|
7 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01921543 |
s28650 |
DBSTRD |
January 2005 |
October 2013 |
October 2013 |
August 13, 2013 |
July 16, 2015 |
|
- UZ Leuven
Leuven, Vlaams-Brabant, Belgium
|
|
| 50 |
NCT02830399 |
Recruiting |
Clinical Trial on Efficacy of rTMS to Improve ECT in Treatment-Resistant Depression |
- Major Depressive Disorder
|
- Device: active rTMS-ECT
- Device: sham rTMS-ECT
|
Interventional
|
Not Applicable |
- Centre Hospitalier du Rouvray
- University Hospital, Rouen
- Centre Hospitalier Henri Laborit
- University Hospital, Caen
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Relative improvement of the Hamilton Rating Scale for Depression 21-items score
|
84 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02830399 |
2015-A01810-49 |
STIMAGNECT |
July 2016 |
August 2019 |
August 2019 |
July 12, 2016 |
November 29, 2016 |
|
- Centre Esquirol- CHU de Caen
Caen, France - Centre Hospitalier Laborit
Poitiers, France - Centre Hospitalier du Rouvray
Sotteville-lès-Rouen, France
|
|
| 51 |
NCT01880593 |
Completed
Has Results |
Ketamine Plus Lithium in Treatment-Resistant Depression |
|
- Drug: Lithium
- Drug: Ketamine
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Icahn School of Medicine at Mount Sinai
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- MADRS-S Score
- QIDS-SR Score
- CGI-S Score
- (and 4 more...)
|
34 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT01880593 |
GCO 13-0365 |
|
July 2013 |
November 2016 |
November 2016 |
June 19, 2013 |
July 31, 2018 |
July 31, 2018 |
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
|
|
| 52 |
NCT00608543 |
Completed
Has Results |
Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression |
- Major Depressive Disorder
|
|
Interventional
|
Phase 4 |
- University of Texas Southwestern Medical Center
- Bristol-Myers Squibb
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Stockings of Cambridge (SOC) Mean Initial Thinking Time for 3-move Problems
- Stockings of Cambridge (SOC) Mean Initial Thinking Time for 5-move Problems
- Spatial Working Memory (SWM) Between Errors for 6-move Problems
- (and 3 more...)
|
17 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00608543 |
042004-011 |
|
October 2005 |
January 2009 |
January 2009 |
February 6, 2008 |
October 26, 2012 |
October 26, 2012 |
- University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, United States
|
|
| 53 |
NCT03317678 |
Suspended |
Fermented Milk Product With Probiotic and Its Impact on Mood of Patients With Treatment Resistant Depression |
|
- Dietary Supplement: BioKefir
- Dietary Supplement: Non-fermented milk
|
Interventional
|
Not Applicable |
- Rush University Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Changes in total score on the Montgomery-Åsberg Depression Rating
- Changes in Clinical Global Impression-Severity Scale (CGI)
- Change in total score on the Computerized Adaptive Testing for Depression (CAT-D)
- Analysis of Intestinal Microbiota pre and post intervention
|
40 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT03317678 |
16060902 |
|
February 10, 2017 |
February 10, 2020 |
March 10, 2020 |
October 23, 2017 |
July 25, 2018 |
|
- RushUMC
Chicago, Illinois, United States
|
|
| 54 |
NCT02914769 |
Completed |
Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression |
|
- Drug: Ayahuasca
- Drug: placebo
|
Interventional
|
Phase 1
Phase 2 |
- Universidade Federal do Rio Grande do Norte
- University of Sao Paulo
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- HAM-D effect at D7
- MADRS effect at D1, D2 and D7
- Response rate at D7 (HAM-D)
- (and 3 more...)
|
35 |
All |
18 Years to 60 Years (Adult) |
NCT02914769 |
CNPq-466760/2014-0 |
|
February 2014 |
December 2016 |
December 2016 |
September 26, 2016 |
February 17, 2017 |
|
- Draulio B de Araujo
Natal, Rio Grande do Norte, Brazil
|
|
| 55 |
NCT01304147 |
Completed
Has Results |
Intranasal Ketamine in Treatment-Resistant Depression |
- Major Depressive Disorder
|
- Drug: Ketamine
- Drug: placebo
|
Interventional
|
Not Applicable |
- James Murrough
- Icahn School of Medicine at Mount Sinai
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Montgomery-Asberg Depression Rating Scale (MADRS)
- Systematic Assessment for Treatment Emergent Effects (SAFTEE)
|
20 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT01304147 |
GCO 11-0492
INKET-001 |
|
October 2011 |
October 2014 |
October 2014 |
February 25, 2011 |
February 8, 2017 |
February 8, 2017 |
- Icahn School of Medicine at Mount Sinai
New York City, New York, United States
|
|
| 56 |
NCT02078817 |
Completed |
Ketamine in Adolescents With Treatment-Resistant Depression |
- Major Depressive Disorder
|
|
Interventional
|
Phase 2 |
- University of Minnesota - Clinical and Translational Science Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical Global Impression
- Children's Depression Rating Scale-Revised
- Montgomery-Åsberg Depression Rating Scale (MADRS)
- (and 7 more...)
|
14 |
All |
12 Years to 18 Years (Child, Adult) |
NCT02078817 |
22225 |
|
September 2014 |
March 2018 |
March 2018 |
March 5, 2014 |
March 6, 2018 |
|
- University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 57 |
NCT02383693 |
Unknown † |
Maintenance rTMS for Treatment-resistant Depression (TRD): a One-year Double Blind Controlled Study |
- Major Depressive Disorder
|
- Device: Repetitive Transcranial Magnetic Stimulation
|
Interventional
|
Phase 2
Phase 3 |
- Centre hospitalier de Ville-Evrard, France
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- 'Hamilton depression rating scale (HDRS)
|
40 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02383693 |
2007-A00244-49 |
TMS/DEP |
January 2007 |
December 2015 |
December 2015 |
March 9, 2015 |
March 9, 2015 |
|
- Unité de Recherche Clinique
Neuilly Sur Marne, Île de France, France
|
|
| 58 |
NCT02974296 |
Recruiting |
Neuroimaging in Patients Undergoing TMS for Depression |
- Treatment Resistant Depression
|
- Device: transcranial magnetic stimulation
|
Interventional
|
Not Applicable |
- New York State Psychiatric Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in functional connectivity measured by resting-state MRI
- Change in depressive symptoms measured by the Hamilton depression rating scale (HDRS)
|
60 |
All |
18 Years to 60 Years (Adult) |
NCT02974296 |
7159 |
NIPUTFD |
April 30, 2017 |
December 2019 |
December 2019 |
November 28, 2016 |
July 19, 2018 |
|
- New York State Psychiatric Institute
New York, New York, United States
|
|
| 59 |
NCT00203723 |
Terminated |
Use of Risperidone in ECT for Treatment Resistant Depression |
|
|
Interventional
|
Phase 4 |
- University of California, Los Angeles
- Janssen, LP
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Scores on depression scales after 6 ECT treatments
- Scores on Clinical Global Impression Scales and Symptom Checklist
|
45 |
All |
18 Years to 89 Years (Adult, Older Adult) |
NCT00203723 |
UCLA IRB #03-10-049-01
RIS-DEP-405 |
|
March 2005 |
|
May 2006 |
September 20, 2005 |
May 18, 2006 |
|
- UCLA Npi&H
Los Angeles, California, United States
|
|
| 60 |
NCT00284791 |
Terminated |
Lamotrigine in Treatment Resistant Depression in Adolescents |
|
- Drug: Lamotrigine (drug)
- Drug: Fluoxetine (drug)
- Drug: sertraline (drug)
|
Interventional
|
Not Applicable |
- Maine Medical Center
- GlaxoSmithKline
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
|
50 |
All |
13 Years to 18 Years (Child, Adult) |
NCT00284791 |
MMC-2571 |
|
January 2006 |
February 2007 |
February 2007 |
February 1, 2006 |
May 17, 2017 |
|
- Maine Medical Center Outpatient Psychiatry
Portland, Maine, United States
|
|
| 61 |
NCT01282632 |
Completed |
Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression |
- Subjects Had Unipolar, Non-psychotic Major Depression
|
- Drug: Risperidone
- Drug: Olanzapine
|
Interventional
|
Phase 1
Phase 2 |
- Sunnybrook Health Sciences Centre
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from Baseline in Hamilton Depression Rating Scale at 1 week
- Change from Baseline in Montgomery Asberg Depression Scale (MADRS)at 1 week
- Change from baseline Hamilton Rating Scale for Anxiety (HAM-A) at 1 week
- (and 17 more...)
|
42 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01282632 |
ro123 |
|
August 2002 |
March 2004 |
March 2004 |
January 25, 2011 |
January 25, 2011 |
|
- Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
|
|
| 62 |
NCT02522377 |
Completed |
Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression |
- Treatment Resistant Depression
- Major Depressive Disorder
- Severe Depression
|
- Drug: Ketamine
- Drug: Midazolam
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale
|
14 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02522377 |
Ketamine ECT |
|
August 2015 |
March 1, 2018 |
March 1, 2018 |
August 13, 2015 |
March 29, 2018 |
|
- Cleveland Clinic Foundation Center for Behavioral Health
Cleveland, Ohio, United States
|
|
| 63 |
NCT02356107 |
Completed
Has Results |
5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females |
- Major Depressive Disorder
|
- Drug: 5-hydroxytryptophan and Creatine monohydrate
|
Interventional
|
Phase 4 |
- Perry Renshaw
- University of Utah
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change From Baseline in Hamilton Depression Rating Scale
|
15 |
Female |
18 Years to 64 Years (Adult) |
NCT02356107 |
5HTP/Creatine |
|
April 2015 |
August 2016 |
August 2016 |
February 5, 2015 |
January 29, 2018 |
January 4, 2018 |
- University of Utah/The Brain Institute
Salt Lake City, Utah, United States
|
|
| 64 |
NCT03283670 |
Active, not recruiting |
Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies |
- Depressive Disorder, Major
- Depressive Disorder, Treatment-Resistant
|
- Drug: Nitrous Oxide 25%
- Drug: Nitrous Oxide 50%
- Drug: Placebo Gas
|
Interventional
|
Phase 2 |
- Washington University School of Medicine
- Brain & Behavior Research Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in depression symptoms measured by the Hamilton Depression Rating Scale- 21 items
|
30 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03283670 |
201608024 |
NARSAD |
September 2016 |
September 2019 |
September 2019 |
September 14, 2017 |
October 15, 2018 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States
|
|
| 65 |
NCT01204918 |
Completed
Has Results |
Efficacy and Tolerability of Riluzole in Treatment Resistant Depression |
|
- Drug: Riluzole
- Drug: placebo
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Montgomery and Asberg Depression Rating Scale (MADRS)
- Responders Having at Least a 50% Improvement in MADRS Compared to the Baseline
- Systematic Assessment for Treatment Emergent Events (SAFTEE-SI)
|
104 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01204918 |
HIC#0903004917 |
|
June 2011 |
May 2015 |
August 2015 |
September 17, 2010 |
February 8, 2018 |
February 8, 2018 |
- Yale University, Yale Depression Research Program
New Haven, Connecticut, United States - Massachussettes General Hospital, Depression Clinical and Research Center
Boston, Massachusetts, United States - Baylor College of Medicine
Houston, Texas, United States
|
|
| 66 |
NCT00273624 |
Terminated |
Olanzapine Augmentation Therapy in Treatment-resistant Depression: a Double-blind Placebo-controlled Trial |
- Therapy-resistant Depression
|
- Drug: Olanzapine
- Drug: Placebo
|
Interventional
|
Phase 3 |
- University Hospital Freiburg
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton-Depression-Scale- HAM-D
- rate of remission (HAM-D less or equal 7)
- differences in HAM-D total scores
- (and 5 more...)
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00273624 |
Olanzapine Augmentation |
|
June 2005 |
December 2009 |
December 2009 |
January 9, 2006 |
May 13, 2016 |
|
- Dept. of Psychiatry, University of Freiburg
Freiburg, Germany
|
|
| 67 |
NCT01426516 |
Terminated
Has Results |
Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1) |
- Major Depressive Disorder
|
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
|
- Efficacy Measured by Change in Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR), Adjusted for Baseline Severity, at 6 Months
- Clinician Behavior as Measured by Change in Recorded Treatment Choice Before and After the Assay Results Are Made Available.
- Quality of Life as Measured by Self Reported Assessment of Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ)
- (and 2 more...)
|
29 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01426516 |
AG1-0001/2 |
PAGE-1_AG1 |
September 2011 |
June 2014 |
June 2014 |
August 31, 2011 |
November 30, 2015 |
November 30, 2015 |
- Centerstone
Nashville, Tennessee, United States
|
|
| 68 |
NCT03027362 |
Recruiting |
Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression |
- Depressive Disorder, Major
|
- Other: Cognitive behavioral therapy (CBT) and medication
- Other: Psychoeducation and medication
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to relapse of depression measured by the Montgomery-Asberg Depressive Rating Scale (MADRS) score.
- Change in cognitive flexibility-working memory
- Change in cognitive flexibility-executive function
|
28 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03027362 |
1609018450 |
|
January 2017 |
July 2019 |
July 2019 |
January 23, 2017 |
June 14, 2018 |
|
- Yale University
New Haven, Connecticut, United States
|
|
| 69 |
NCT00276978 |
Terminated |
Aripiprazole Augmentation Therapy in Treatment-resistant Depression |
- Therapy-resistant Depression
|
|
Interventional
|
Phase 3 |
- University Hospital Freiburg
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- rate of response as defined by a more or equal 50 % reduction of baseline HAM-D (Hamilton Depression Rating scale)
|
20 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00276978 |
Aripiprazole Augmentation |
|
June 2005 |
November 2009 |
November 2009 |
January 13, 2006 |
May 13, 2016 |
|
- Dept. of Psychiatry, University of Freiburg
Freiburg, Germany
|
|
| 70 |
NCT01239888 |
Unknown † |
Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression - A Pilot Study |
- Depression
- Major Depressive Disorder
|
- Drug: Oxytocin
- Drug: Oxytocin and Tibolone
- Drug: Placebo
|
Interventional
|
Phase 1 |
- The Alfred
- Monash University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS)
- Change from baseline in Hamilton Rating Scale for Depression (HAM-D)
- Change from baseline in Beck Depression Inventory II (BDI-II)
- (and 5 more...)
|
15 |
Female |
18 Years to 45 Years (Adult) |
NCT01239888 |
MAPRC 2010CK |
|
January 2012 |
November 2012 |
|
November 15, 2010 |
January 18, 2012 |
|
- Monash Alfred Psychiatry Research Centre
Melbourne, Victoria, Australia
|
|
| 71 |
NCT01913535 |
Terminated
Has Results |
Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression |
- Treatment Resistant Depression
|
- Drug: CERC-501
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Massachusetts General Hospital
- National Institute of Mental Health (NIMH)
- Butler Hospital
- (and 3 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Hamilton Rating Scale for Depression - 6 Items (HAM-D-6)
- Change in Hamilton Rating Scale for Depression - 6 Items (HAM-D-6), Day 20
- Number of Participants With Response on Hamilton Rating Scale for Depression - 6 Items (HAM-D-6)
- (and 10 more...)
|
8 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01913535 |
RAP-002
271201100006I-0-27100007-1 |
RAPID KOR |
September 12, 2013 |
January 22, 2016 |
January 22, 2016 |
August 1, 2013 |
July 2, 2017 |
July 2, 2017 |
- Rush University
Chicago, Illinois, United States - University of Kansas
Wichita, Kansas, United States - Temple University
Philadelphia, Pennsylvania, United States - Brown University-Butler Hospital
Providence, Rhode Island, United States
|
|
| 72 |
NCT03667872 |
Not yet recruiting |
Efficacy and Safety of DBS in Patients With Treatment-Resistant Depression |
- Treatment Resistant Depressive Disorder
|
- Procedure: Bilateral implantation of DBS system to Habeluna
|
Interventional
|
Not Applicable |
- Beijing Pins Medical Co., Ltd
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in the Hamilton Depression Scale
|
6 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03667872 |
PINS-029 |
|
September 18, 2018 |
June 18, 2020 |
June 18, 2022 |
September 12, 2018 |
September 12, 2018 |
|
- Habenula DBS
Shenzhen, Shenzhen, China
|
|
| 73 |
NCT01507155 |
Completed
Has Results |
An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay |
- Treatment Resistant Depression
- Generalized Anxiety Disorder
|
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Change From Baseline in Clinical Global Impressions Improvement (CGI-I) Scale at 3 Months
- Efficacy Measured by QIDS-SR16, Q-LES-Q-SF, UKU Side Effects; and SAS at 3 Months
|
685 |
All |
18 Years and older (Adult, Older Adult) |
NCT01507155 |
COM-1 |
COM-1 |
April 2013 |
May 2014 |
May 2014 |
January 10, 2012 |
June 8, 2016 |
May 2, 2016 |
- Genomind, LLC
Chalfont, Pennsylvania, United States
|
|
| 74 |
NCT03290963 |
Withdrawn |
Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine |
- Treatment Resistant Depression
|
- Drug: Lithium
- Drug: Placebo
- Drug: Ketamine
|
Interventional
|
Phase 2 |
- William V. Bobo, M.D.
- Mayo Clinic
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Change in Montgomery-Asberg Depression Rating Scale (MADRS)
|
0 |
All |
18 Years to 64 Years (Adult) |
NCT03290963 |
17-000819 |
|
November 30, 2017 |
December 2018 |
December 2018 |
September 25, 2017 |
August 16, 2018 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
|
| 75 |
NCT01984710 |
Recruiting |
DBS for TRD Medtronic Activa PC+S |
- Treatment Resistant Depression
|
- Device: Medtronic Activa PC+S System
|
Interventional
|
Not Applicable |
- Emory University
- Hope for Depression Research Foundation
- The Dana Foundation
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Activa PC+S LFP recordings
|
20 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01984710 |
IRB00066843 |
|
September 2013 |
September 2023 |
September 2023 |
November 15, 2013 |
November 7, 2018 |
|
- Emory University
Atlanta, Georgia, United States
|
|
| 76 |
NCT00533832 |
Completed |
Pivotal Trial (D02) of Vagus Nerve Stimulation (VNS) for Treatment-Resistant Depression (TRD) |
- Major Depressive Disorder
|
- Device: vagus nerve stimulation (VNS)
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
|
266 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00533832 |
D02 |
|
July 2000 |
|
July 2005 |
September 24, 2007 |
September 24, 2007 |
|
- Houston, Texas, United States
|
|
| 77 |
NCT03191058 |
Recruiting |
Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression |
- Depression
- Unipolar Depression
- Treatment Resistant Depression
|
- Device: Magnetic Seizure Therapy
- Device: Electroconvulsive Therapy
|
Interventional
|
Not Applicable |
- University of Texas Southwestern Medical Center
- National Institute of Mental Health (NIMH)
- Centre for Addiction and Mental Health
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Improvement in symptom severity of depression as measured by the Hamilton Rating Scale for Depression - 24 (HRSD-24)
- Cognitive adverse effects as indexed by the Autobiographical Memory Test (AMT)
- Improvement in symptom severity of Suicidal Ideation as measured by the Scale for Suicidal Ideation (SSI)
|
260 |
All |
18 Years and older (Adult, Older Adult) |
NCT03191058 |
CREST-MST
1R01MH112815-01 |
CREST-MST |
June 25, 2018 |
July 2022 |
July 2022 |
June 19, 2017 |
August 14, 2018 |
|
- University of Texas Southwestern Medical Center
Dallas, Texas, United States - Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health
Toronto, Ontario, Canada
|
|
| 78 |
NCT00491686 |
Completed |
AZD6765 for Treatment Resistant Depression |
|
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- The primary objective is to determine whether an antidepressant effect can be achieved in patients with Treatment Resistant Depression determined by a change from baseline in the MADRS total score.
- The secondary objective is to assess the safety and tolerability of AZD6765 as assessed by vital signs, physical examination, clinical laboratory evaluations, ECG's and incidence of adverse events.
|
34 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT00491686 |
D6702C00001 |
|
July 2007 |
November 2007 |
November 2007 |
June 26, 2007 |
January 21, 2011 |
|
- Research Site
Glendale, California, United States - Research Site
Hartford, Connecticut, United States - Research Site
New Haven, Connecticut, United States - (and 2 more...)
|
|
| 79 |
NCT02977299 |
Recruiting |
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD |
- Treatment Resistant Major Depressive Disorder
|
- Drug: Aripiprazole
- Device: Repetitive transcranial magnetic stimulation (rTMS)
- Drug: Venlafaxine XR
|
Interventional
|
Phase 4 |
- Massachusetts General Hospital
- Patient-Centered Outcomes Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Montgomery-Asberg Depression Rating Scale (MADRS)
- Quality of Life, Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)
|
639 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02977299 |
2015P002430 |
ASCERTAINTRD |
May 1, 2017 |
October 2021 |
January 2022 |
November 30, 2016 |
June 21, 2018 |
|
- The University of Alabama School of Medicine
Birmingham, Alabama, United States - Ronald Reagan UCLA Medical Center
Los Angeles, California, United States - Stanford University
Stanford, California, United States - (and 15 more...)
|
|
| 80 |
NCT02181231 |
Completed |
Buprenorphine Used With Treatment Resistant Depression in Older Adults |
- Major Depressive Disorder
- Depression
|
- Drug: venlafaxine XR
- Drug: buprenorphine
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- Washington University School of Medicine
- Reckitt Benckiser LLC
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Montgomery-Asberg Depression Rating Scale (MADRS)
- Frequency, Intensity, and Burden of Side Effects Rating (FIBSER)
- Antidepressant Side Effect Checklist (ASEC)
- (and 3 more...)
|
43 |
All |
50 Years and older (Adult, Older Adult) |
NCT02181231 |
201406016
IND 123020
IND 130774 |
IRL Grey B |
June 1, 2016 |
April 30, 2018 |
April 30, 2018 |
July 3, 2014 |
September 13, 2018 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States
|
|
| 81 |
NCT02810717 |
Recruiting |
Effects of TBS on 5-HT1A Receptor Binding |
- Treatment Resistant Depression
|
- Device: theta-burst stimulation using a MagPro X1000
- Device: sham stimulation using a MagPro X1000
|
Interventional
|
Not Applicable |
- Rupert Lanzenberger
- Medical University of Vienna
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Regional 5-HT1A receptor binding
- Regional white matter microstructure using DWI-TBSS
- Regional white matter microstructure using DWI-Tractography
- (and 3 more...)
|
80 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02810717 |
1.3 |
|
December 2016 |
November 2019 |
November 2019 |
June 23, 2016 |
August 16, 2018 |
|
- Department of Psychiatry and Psychotherapy, Medical University of Vienna
Vienna, Austria
|
|
| 82 |
NCT03149991 |
Recruiting |
A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD) |
|
- Drug: Brexpiprazole
- Drug: Ketamine
- Drug: Placebo
|
Interventional
|
Phase 4 |
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Symptoms of Depression Questionnaire (SDQ)
|
50 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03149991 |
KETBREX001 |
|
September 14, 2017 |
December 31, 2018 |
January 31, 2019 |
May 11, 2017 |
August 15, 2018 |
|
- Collaborative Neuroscience Network, LLC.
Garden Grove, California, United States - Pacific Research Partners, LLC
Oakland, California, United States - Rush University Medical Center
Chicago, Illinois, United States - (and 3 more...)
|
|
| 83 |
NCT00070694 |
Completed |
An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression |
|
|
Interventional
|
Phase 2 |
- National Institute of Mental Health (NIMH)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
|
96 |
All |
Child, Adult, Older Adult |
NCT00070694 |
030315
03-M-0315 |
|
September 2003 |
|
October 2004 |
October 7, 2003 |
March 4, 2008 |
|
- National Institute of Mental Health (NIMH)
Bethesda, Maryland, United States
|
|
| 84 |
NCT02778035 |
Recruiting |
Comparing Different Patterns of rTMS in Major Depression |
- Depression; Bipolar Disorder
|
- Device: Dorsomedial prefrontal rTMS
|
Interventional
|
Not Applicable |
- University Health Network, Toronto
- Centre for Addiction and Mental Health
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- 17-Item Hamilton Rating Scale for Depression (HAMD-17)
- Beck Depression Inventory-II (BDI-II)
|
180 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02778035 |
15-9615 |
|
April 2016 |
March 2019 |
September 2019 |
May 19, 2016 |
March 14, 2018 |
|
- UHN MRI-Guided rTMS Clinic, Toronto Western Hospital
Toronto, Ontario, Canada - Centre for Addiction and Mental Health
Toronto, Ontario, Canada
|
|
| 85 |
NCT01162434 |
Completed |
Brain MRI (Magnetic Resonance Imaging) Scans of Patients With Treatment Resistant Depression (TRD) and Healthy Controls |
|
|
Observational
|
|
- University of Bristol
- North Bristol NHS Trust
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Region of interest analysis
- Whole brain analysis
- Comparison of abnormalities
|
21 |
All |
26 Years to 64 Years (Adult) |
NCT01162434 |
UoB1112
10/H0102/15 |
|
February 2010 |
February 2012 |
February 2012 |
July 14, 2010 |
July 12, 2012 |
|
- Bristol Royal Infirmary
Bristol, United Kingdom
|
|
| 86 |
NCT02882711 |
Enrolling by invitation |
The UTHealth Ketamine Project |
- Treatment Resistant Depression
- Major Depressive Disorder
- Bipolar Disorder
|
|
Interventional
|
Phase 2 |
- The University of Texas Health Science Center, Houston
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety will be measured through number of adverse events
- Efficacy of treatment will be measured on of Clinical Global Impressions (CGI)
- Reduction in severity of depressive symptoms will be measured using the Montgomery-Asberg Depression Rating Scale (MADRS)
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02882711 |
HSC-MS-16-0020 |
|
August 2016 |
March 31, 2019 |
March 31, 2019 |
August 30, 2016 |
October 10, 2018 |
|
- The University of Texas Health Science Center at Houston
Houston, Texas, United States
|
|
| 87 |
NCT01920555 |
Completed
Has Results |
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD) |
- Treatment Resistant Depression
|
- Drug: Ketamine
- Drug: Placebo Midazolam
|
Interventional
|
Phase 2 |
- Massachusetts General Hospital
- National Institute of Mental Health (NIMH)
- Baylor College of Medicine
- (and 4 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Rating Scale for Depression - 6 Items
- Montgomery-Asberg Depression Rating Scale (MADRS)
- Clinical Global Impressions-Severity (CGI-S)
- (and 7 more...)
|
99 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01920555 |
RAP-003
271201100006I-0-27100007-1 |
|
December 2014 |
January 2017 |
February 2017 |
August 12, 2013 |
June 19, 2018 |
April 17, 2018 |
- Stanford University
Palo Alto, California, United States - Yale University
New Haven, Connecticut, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - (and 3 more...)
|
|
| 88 |
NCT02095639 |
Terminated |
Inflammation and Electroconvulsive Therapy |
- Major Depressive Disorder
|
|
Observational
|
|
- Centre for Addiction and Mental Health
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in translocator protein distribution volume (TSPO Vt) measured by [18F]FEPPA PET
- 17-item Hamilton Depression Rating Scale (HDRS)
- Neurocognitive Battery
- Peripheral Inflammatory Markers
|
5 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02095639 |
074-2012 |
|
August 2012 |
March 2017 |
May 2017 |
March 26, 2014 |
February 14, 2018 |
|
- Centre for Addiction and Mental Health
Toronto, Ontario, Canada
|
|
| 89 |
NCT03472638 |
Active, not recruiting |
Dorsomedial rTMS For Depression In Borderline Personality Disorder |
- Borderline Personality Disorder
- Major Depression
|
- Device: Dorsomedial prefrontal rTMS
|
Interventional
|
Not Applicable |
- University Health Network, Toronto
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- HRSD-17 change
- ZAN-BPD change
|
20 |
Female |
18 Years to 65 Years (Adult, Older Adult) |
NCT03472638 |
15-9928 |
rTMS |
July 2016 |
December 2017 |
July 2018 |
March 21, 2018 |
March 21, 2018 |
|
- Toronto Western Hospital
Toronto, Ontario, Canada
|
|
| 90 |
NCT02994433 |
Recruiting |
NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits |
- Depressive Disorder, Major
- Depressive Disorder, Treatment-Resistant
|
- Drug: Nitrous Oxide
- Drug: Placebo gas
- Device: MRI
|
Interventional
|
Phase 1 |
- Washington University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Comparison of functional connectivity between default mode network of treatment-resistant depressed and non-depressed participants
- Comparison of functional connectivity between affective network of treatment-resistant depressed and non-depressed participants
- Comparison of functional connectivity between cognitive control network of treatment-resistant depressed and non-depressed participants
- Comparison of functional connectivity between dorsal nexus of treatment-resistant depressed and non-depressed participants
|
40 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02994433 |
201606120 |
|
July 2016 |
June 2019 |
June 2019 |
December 15, 2016 |
July 25, 2018 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States
|
|
| 91 |
NCT03240692 |
Enrolling by invitation |
Accelerated Theta Burst Stimulation in Treatment-Resistant Depression |
- Treatment Resistant Depression
|
- Device: Accelerated theta burst treatment
|
Interventional
|
Not Applicable |
- Stanford University
- Schatzberg, Alan, M.D.
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline functional connectivity in immediate post-treatment
- Montgomery Asberg Depression Rating Scale (MADRS)
- Columbia Suicide Severity Rating Scale (C-SSRS)
- (and 4 more...)
|
30 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03240692 |
33797 |
aTBS |
May 1, 2017 |
September 30, 2019 |
September 30, 2020 |
August 7, 2017 |
August 9, 2018 |
|
- Nolan Williams, MD
Palo Alto, California, United States
|
|
| 92 |
NCT00837486 |
Completed
Has Results |
Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant Depression |
|
- Device: Reclaim™ DBS System
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Responders
- Depression Change
- Quality of Life Change
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT00837486 |
1626
G080033 |
|
February 2009 |
December 2010 |
April 2013 |
February 5, 2009 |
May 28, 2015 |
May 28, 2015 |
- Massachusetts General Hospital
Charlestown, Massachusetts, United States - Cleveland Clinic Foundation
Cleveland, Ohio, United States - University of Pennsylvania
Philadelphia, Pennsylvania, United States - (and 2 more...)
|
|
| 93 |
NCT03428828 |
Recruiting |
Neurofeedback for Treatment Resistant Depression |
- Treatment Resistant Depression
|
- Behavioral: Amygdala Neurofeedback
- Behavioral: Parietal Neurofeedback
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Beck Depression Inventory (BDI-II)
- Amygdala Activity
|
100 |
All |
18 Years to 55 Years (Adult) |
NCT03428828 |
PRO18010596 |
|
September 1, 2018 |
March 1, 2023 |
March 31, 2023 |
February 12, 2018 |
September 10, 2018 |
|
- University of Pittsburgh
Pittsburgh, Pennsylvania, United States
|
|
| 94 |
NCT01353092 |
Completed |
Pulsating ElectroMagnetive Treatment (PEMF) at Treatment Resistant Depression |
- Treatment Resistant Depression
|
- Device: Re5 Pulsating ElectroMagnetic Fields
- Device: Re5 Pulsating ElectroMagnetic Fields (PEMF)
|
Interventional
|
Phase 3 |
- Hillerod Hospital, Denmark
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton depression rating scale
- UKU
|
65 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT01353092 |
26.04.2010 |
PEMFII |
April 2011 |
June 2013 |
June 2013 |
May 12, 2011 |
August 26, 2015 |
|
- Psychiatric Research Unit, Mental Health Centre North Zealand
Hilleroed, Denmark
|
|
| 95 |
NCT03361826 |
Recruiting |
Magnetic Seizure Therapy for the Treatment of Borderline Personality Disorder |
- Borderline Personality Disorder
|
- Device: MagPro MST
- Behavioral: DBT
|
Interventional
|
Not Applicable |
- Centre for Addiction and Mental Health
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Improvement in symptom severity of depression as measured by the Hamilton Rating Scale for Depression - 24
- Improvement in symptom severity of Suicidal Ideation as measured by the Modified Scale for Suicidal Ideation
|
30 |
Female |
18 Years to 50 Years (Adult) |
NCT03361826 |
053/2015 |
|
October 17, 2017 |
December 31, 2018 |
December 17, 2019 |
December 5, 2017 |
September 12, 2018 |
|
- Centre for Addiction and Mental Health
Toronto, Ontario, Canada
|
|
| 96 |
NCT02379767 |
Unknown † |
Effects of ECT on Monoamine Oxidase A in Depression Investigated With PET |
|
- Device: Electroconvulsive therapy
- Other: Positron emission tomography of the brain using [11C]harmine
- Other: Structural magnetic resonance imaging
|
Observational
|
|
- Medical University of Vienna
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Monoamine oxidase A distribution volume in the brain
- Grey matter volume
|
36 |
All |
16 Years to 60 Years (Child, Adult) |
NCT02379767 |
v1.2_201502 |
|
March 2015 |
February 2018 |
February 2018 |
March 5, 2015 |
September 14, 2016 |
|
- Department of Psychiatry and Psychotherapy
Vienna, Austria
|
|
| 97 |
NCT02800226 |
Completed |
Pilot Study Comparing 10hz vs Theta Burst Stimulation |
- Major Depressive Disorder
|
|
Interventional
|
Phase 3 |
- University of British Columbia
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in the Hamilton Depression Rating scale 17-item (HDRS-17) score
|
20 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02800226 |
H13-02340 |
|
March 2014 |
May 2015 |
May 2015 |
June 15, 2016 |
August 10, 2018 |
|
- Non-Invasive Neurostimulation Therapies lab, University of British Columbia
Vancouver, British Columbia, Canada
|
|
| 98 |
NCT03701724 |
Not yet recruiting |
Cost-utility Analysis of Maintenance rTMS for Treatment-resistant Depression |
- Treatment-resistant Depression
|
- Device: Systematic maintenance rTMS
- Device: rTMS course in case of relapse
- Device: sham rTMS
|
Interventional
|
Not Applicable |
- Nantes University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- Cost-utility ratio, according to collective perspective of rTMS use in TRD compared to conventional therapeutic approaches without active rTMS.
- Budget impact analysis of spreading the most efficient strategy for using rTMS (systematic mTMS or rTMS course in case of relapse).
- Major depressive disorder history
- (and 24 more...)
|
318 |
All |
18 Years and older (Adult, Older Adult) |
NCT03701724 |
RC17_0494 |
ACOUSTIM |
October 15, 2018 |
October 15, 2021 |
October 30, 2022 |
October 10, 2018 |
October 10, 2018 |
|
- Nantes University Hospital
Nantes, France
|
|
| 99 |
NCT01801319 |
Active, not recruiting |
A Clinical Evaluation of Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression |
- Treatment Resistant Depression
- Depressive Disorder
|
- Device: Libra Deep Brain Stimulation System
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Primary Efficacy: Changes in the Hamilton Depression Rating Scale-17
- The incidence of all adverse events
- Showing SCG-DBS significantly increases health related quality of life compared to sham stimulation in patients with TRD
|
40 |
All |
21 Years to 70 Years (Adult, Older Adult) |
NCT01801319 |
C-08-07
Health Canada 148956 |
|
June 2011 |
June 2017 |
December 2017 |
February 28, 2013 |
April 26, 2017 |
|
- Toronto General Hospital
Toronto, Ontario, Canada
|
|
| 100 |
NCT02960763 |
Recruiting |
Optimizing Outcomes of Treatment-Resistant Depression in Older Adults |
- Treatment Resistant Depression
- Major Depressive Disorder
- Treatment-Refractory Depression
- (and 2 more...)
|
- Drug: Aripiprazole Augmentation
- Drug: Bupropion Augmentation
- Drug: Switch to bupropion
- (and 2 more...)
|
Interventional
|
Phase 4 |
- Washington University School of Medicine
- Patient-Centered Outcomes Research Institute
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Psychological Well-Being
- Remission from Depression
- Serious Adverse Events
- (and 6 more...)
|
1500 |
All |
60 Years and older (Adult, Older Adult) |
NCT02960763 |
TRD-1511-33321
201609085 |
OPTIMUM |
February 24, 2017 |
September 2021 |
December 2021 |
November 10, 2016 |
July 19, 2018 |
|
- UCLA Late-Life Mood, Stress, and Wellness Research Program
Los Angeles, California, United States - Washington University School of Medicine Healthy Mind Lab
Saint Louis, Missouri, United States - Columbia University Adult and Late Life Depression Clinic
New York, New York, United States - (and 2 more...)
|
|
Create an RSS feed from your search for:
Download the search results for: